OBJECTIVES: To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma. METHODS: This multi-institutional non-randomized phase II trial enrolled two cohorts: patients with uterine carcinoma (cohort A) and uterine carcinosarcoma (cohort B). Eligibility criteria included measurable disease, 0-1 prior chemotherapy regimens, and ECOG performance status <or=2. Sorafenib at a dose of 400 mg was administered orally twice daily. A cycle was defined as 28 days. Objective tumor response was the primary endpoint and was assessed following every two cycles. RESULTS: Fifty-six patients (40 with carcinoma, 16 with carcinosarcoma) were enrolled between March 2005 and August 2007. Two (5%) patients with uterine carcinoma had a partial response (PR) and 17 (42.5%) achieved stable disease (SD). Five had SD lasting at least 4 months. The 6-month progression-free survival rate for patients with carcinoma was 29%, and the median overall survival was 11.4 months. No patients with carcinosarcoma had an objective response. Four (25%) had SD, and one had SD lasting 18 months. The 6-month progression-free survival rate was 13%, and the median overall survival was 5.0 months. Grade 3/4 drug related toxicities included: hypertension (13%), hand-foot syndrome (13%), hypophosphatemia (7%), anemia (5%), rash (5%), diarrhea (5%), thrombosis (5%), fatigue (5%) and bleeding (5%). CONCLUSION: Sorafenib had minimal activity in patients with uterine carcinoma. Predictive factors for potential benefit are needed. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVES: To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma. METHODS: This multi-institutional non-randomized phase II trial enrolled two cohorts: patients with uterine carcinoma (cohort A) and uterine carcinosarcoma (cohort B). Eligibility criteria included measurable disease, 0-1 prior chemotherapy regimens, and ECOG performance status <or=2. Sorafenib at a dose of 400 mg was administered orally twice daily. A cycle was defined as 28 days. Objective tumor response was the primary endpoint and was assessed following every two cycles. RESULTS: Fifty-six patients (40 with carcinoma, 16 with carcinosarcoma) were enrolled between March 2005 and August 2007. Two (5%) patients with uterine carcinoma had a partial response (PR) and 17 (42.5%) achieved stable disease (SD). Five had SD lasting at least 4 months. The 6-month progression-free survival rate for patients with carcinoma was 29%, and the median overall survival was 11.4 months. No patients with carcinosarcoma had an objective response. Four (25%) had SD, and one had SD lasting 18 months. The 6-month progression-free survival rate was 13%, and the median overall survival was 5.0 months. Grade 3/4 drug related toxicities included: hypertension (13%), hand-foot syndrome (13%), hypophosphatemia (7%), anemia (5%), rash (5%), diarrhea (5%), thrombosis (5%), fatigue (5%) and bleeding (5%). CONCLUSION:Sorafenib had minimal activity in patients with uterine carcinoma. Predictive factors for potential benefit are needed. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: J Tate Thigpen; Mark F Brady; Howard D Homesley; John Malfetano; Brent DuBeshter; Robert A Burger; Shu Liao Journal: J Clin Oncol Date: 2004-10-01 Impact factor: 44.544
Authors: David B T La Vine; Teresa A Coleman; Carol H Davis; Christine E Carbonell; Wendy B Davis Journal: Am J Clin Oncol Date: 2010-06 Impact factor: 2.339
Authors: Gini F Fleming; Virginia L Brunetto; David Cella; Katherine Y Look; Gary C Reid; Adnan R Munkarah; Richard Kline; Robert A Burger; Annekathryn Goodman; R Tucker Burks Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Kathleen N Moore; Michael W Sill; Meaghan E Tenney; Christopher J Darus; David Griffin; Theresa L Werner; Peter G Rose; Robert Behrens Journal: Gynecol Oncol Date: 2015-07-11 Impact factor: 5.482
Authors: H J Mackay; R J Buckanovich; H Hirte; R Correa; P Hoskins; J Biagi; L P Martin; G F Fleming; R Morgan; L Wang; R Polintan; A M Oza Journal: Gynecol Oncol Date: 2011-12-02 Impact factor: 5.482
Authors: Matthew A Powell; Michael W Sill; Paul J Goodfellow; Doris M Benbrook; Heather A Lankes; Kimberly K Leslie; Yvette Jeske; Robert S Mannel; Monique A Spillman; Paula S Lee; James S Hoffman; D Scott McMeekin; Pamela M Pollock Journal: Gynecol Oncol Date: 2014-07-11 Impact factor: 5.482
Authors: C Wallwiener; A Hartkopf; S Kommoss; C Joachim; M Wallwiener; F A Taran; S Brucker Journal: Geburtshilfe Frauenheilkd Date: 2016-02 Impact factor: 2.915